This report was first published by Endpoints News. To see the original version, click here
The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers.
The Chicago-area pharma giant has signed an agreement that gives it the exclusive option to acquire a little-known biotech named Kestrel Therapeutics for up to $1.45 billion, according to a Tuesday press release from Kestrel. The drug will have to hit certain undisclosed development milestones to bring the acquisition to fruition.
您已阅读16%（591字），剩余84%（3139字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。